BCRX - BioCryst Pharmaceuticals Stock Price, News & Analysis

$4.64 0.11 (2.43 %)
(As of 11/23/2017 03:21 PM ET)
Previous Close$4.53
Today's Range$4.51 - $4.70
52-Week Range$3.95 - $9.25
Volume448,200 shs
Average Volume1.55 million shs
Market Capitalization$445.77 million
P/E RatioN/A
Dividend YieldN/A
Beta3.13

About BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals logoBioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:BCRX
CUSIP09058V10

Debt

Debt-to-Equity Ratio0.21%
Current Ratio2.53%
Quick Ratio2.53%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$26.35 million
Price / Sales17.33
Cash FlowN/A
Price / CashN/A
Book Value$1.02 per share
Price / Book4.55

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($0.64)
Net Income$-55,140,000.00
Net Margins-167.58%
Return on Equity-123.16%
Return on Assets-38.71%

Miscellaneous

Employees65
Outstanding Shares98,400,000

Frequently Asked Questions for BioCryst Pharmaceuticals (NASDAQ:BCRX)

What is BioCryst Pharmaceuticals' stock symbol?

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released its earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.18) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.18). The biotechnology company had revenue of $8.76 million for the quarter, compared to analysts' expectations of $5.05 million. BioCryst Pharmaceuticals had a negative return on equity of 123.16% and a negative net margin of 167.58%. The firm's revenue was up 12.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.16) earnings per share. View BioCryst Pharmaceuticals' Earnings History.

Where is BioCryst Pharmaceuticals' stock going? Where will BioCryst Pharmaceuticals' stock price be in 2017?

10 analysts have issued 1-year price objectives for BioCryst Pharmaceuticals' shares. Their predictions range from $6.00 to $15.00. On average, they anticipate BioCryst Pharmaceuticals' share price to reach $9.71 in the next year. View Analyst Ratings for BioCryst Pharmaceuticals.

What are Wall Street analysts saying about BioCryst Pharmaceuticals stock?

Here are some recent quotes from research analysts about BioCryst Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. " (8/10/2017)
  • 2. Needham & Company LLC analysts commented, "Shire (SHPG) reported positive results from the ph 3 HELP trial evaluating lanadelumab (fka SHP643) as a prophylactic HAE treatment. Lanadelumab, an antibody that binds and inhibits plasma kallikrein, is formulated for subcutaneous administration and has a long half-life (~14 days) that enables once- or twice-monthly dosing. The HELP trial met all of its endpoints; monthly attack rate reduction vs. placebo for all dosing regimens ranged from 73% – 87% (p<0.001). A BLA filing for lanadelumab is expected in late-2017/early-2018. BCRX's BCX7353, a daily orally-administered HAE prophylactic candidate, is currently under evaluation in the ph 2 APeX-1 trial. Positive interim results reported in late-Feb showed that BCX7353 led to a ~52% HAE attack rate reduction (p=0.035, ITT), with results showing a dichotomy of efficacy between peripheral attacks (~88% reduction) and abdominal attacks (~24% reduction). Additional APeX-1 cohorts evaluating lower-doses of BCX7353 are expected to report in 2Q17. These data should provide clarity on the efficacy/tolerability profile of BCX7353 and help shed some light on its potential role in HAE prophylaxis."" (5/19/2017)

Who are some of BioCryst Pharmaceuticals' key competitors?

Who are BioCryst Pharmaceuticals' key executives?

BioCryst Pharmaceuticals' management team includes the folowing people:

  • Robert A. Ingram, Chairman of the Board (Age 74)
  • Jon P. Stonehouse, President, Chief Executive Officer, Director (Age 56)
  • Thomas R. Staab II, Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer (Age 52)
  • Yarlagadda S. Babu Ph.D., Senior Vice President - Drug Discovery (Age 64)
  • Lynne M. Powell, Senior Vice President, Chief Commercial Officer (Age 50)
  • William P. Sheridan, Senior Vice President, Chief Medical Officer (Age 62)
  • Alane P. Barnes, Vice President, General Counsel, and Corporate Secretary (Age 51)
  • Fred E. Cohen Ph.D. M.D., Director (Age 60)
  • Sanj K. Patel, Director (Age 46)
  • George B. Abercrombie, Independent Director (Age 62)

Who owns BioCryst Pharmaceuticals stock?

BioCryst Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (4.61%), VHCP Management II LLC (3.22%), Jennison Associates LLC (3.13%), Artal Group S.A. (0.66%), Alyeska Investment Group L.P. (0.46%) and Schwab Charles Investment Management Inc. (0.33%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Bros Advisors Lp Baker, Fred E Cohen, Thomas R Staab II, William P Sheridan and Yarlagadda S Babu. View Institutional Ownership Trends for BioCryst Pharmaceuticals.

Who sold BioCryst Pharmaceuticals stock? Who is selling BioCryst Pharmaceuticals stock?

BioCryst Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A. and California State Teachers Retirement System. Company insiders that have sold BioCryst Pharmaceuticals company stock in the last year include Fred E Cohen, Thomas R Staab II and William P Sheridan. View Insider Buying and Selling for BioCryst Pharmaceuticals.

Who bought BioCryst Pharmaceuticals stock? Who is buying BioCryst Pharmaceuticals stock?

BioCryst Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Jennison Associates LLC, VHCP Management II LLC, Alyeska Investment Group L.P., ClariVest Asset Management LLC, Swiss National Bank, Allianz Asset Management GmbH and Wells Fargo & Company MN. View Insider Buying and Selling for BioCryst Pharmaceuticals.

How do I buy BioCryst Pharmaceuticals stock?

Shares of BioCryst Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioCryst Pharmaceuticals' stock price today?

One share of BioCryst Pharmaceuticals stock can currently be purchased for approximately $4.64.

How big of a company is BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals has a market capitalization of $445.77 million and generates $26.35 million in revenue each year. The biotechnology company earns $-55,140,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis. BioCryst Pharmaceuticals employs 65 workers across the globe.

How can I contact BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The biotechnology company can be reached via phone at 919-859-1302 or via email at [email protected]


MarketBeat Community Rating for BioCryst Pharmaceuticals (BCRX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  258 (Vote Outperform)
Underperform Votes:  224 (Vote Underperform)
Total Votes:  482
MarketBeat's community ratings are surveys of what our community members think about BioCryst Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 3 Hold Ratings, 7 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.70)
Consensus Price Target: $9.71 (109.36% upside)

Consensus Price Target History for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Price Target History for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Analysts' Ratings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/8/2017HC WainwrightReiterated RatingBuy$10.00N/AView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageSector Perform -> Sector Perform$6.00LowView Rating Details
9/6/2017J P Morgan Chase & CoBoost Price TargetOverweight -> Neutral$4.93 -> $9.00HighView Rating Details
9/6/2017Jefferies Group LLCUpgradeHold -> Buy$5.00 -> $7.00HighView Rating Details
9/5/2017Piper Jaffray CompaniesReiterated RatingOverweight$13.00 -> $15.00HighView Rating Details
8/8/2017Noble FinancialReiterated RatingBuyLowView Rating Details
5/19/2017Needham & Company LLCReiterated RatingHoldMediumView Rating Details
2/16/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$11.00N/AView Rating Details
1/23/2017FBR & CoReiterated RatingOutperformN/AView Rating Details
12/16/2016JMP SecuritiesUpgradeMarket Perform -> Outperform$10.00N/AView Rating Details
2/9/2016Rodman & RenshawLower Price TargetBuy$24.00 -> $10.00N/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Earnings by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Earnings History by Quarter for BioCryst Pharmaceuticals (NASDAQ BCRX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.18)($0.18)$5.05 million$8.76 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.19)($0.21)$5.79 million$3.10 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.20)($0.19)$6.13 million$9.40 millionViewListenView Earnings Details
2/27/2017Q416($0.23)($0.06)$4.13 million$9.00 millionViewListenView Earnings Details
11/7/2016Q316($0.24)($0.16)$5.94 million$7.80 millionViewListenView Earnings Details
8/4/2016Q216($0.26)($0.22)$3.92 million$4.80 millionViewN/AView Earnings Details
5/5/2016Q116($0.23)($0.31)$5.42 million$4.82 millionViewN/AView Earnings Details
2/23/2016Q415($0.26)($0.25)$6.34 million$4.60 millionViewListenView Earnings Details
11/5/2015Q315($0.20)($0.20)$6.77 million$11.00 millionViewListenView Earnings Details
8/7/2015Q215($0.22)$0.06$7.10 million$25.80 millionViewListenView Earnings Details
5/8/2015Q115($0.24)($0.21)$4.30 million$6.80 millionViewListenView Earnings Details
2/18/2015Q414($0.20)($0.16)$3.64 million$5.40 millionViewListenView Earnings Details
11/6/2014Q314($0.20)($0.12)$2.11 million$3.20 millionViewListenView Earnings Details
8/5/2014Q214($0.19)($0.23)$2.32 million$1.50 millionViewN/AView Earnings Details
5/8/2014Q114($0.16)($0.17)$3.34 million$3.50 millionViewN/AView Earnings Details
2/26/2014Q413($0.08)($0.09)$8.81 million$10.60 millionViewN/AView Earnings Details
11/5/2013Q313($0.14)($0.14)$2.01 million$2.40 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.14)($0.23)$2.01 million$0.82 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.15)($0.09)$1.31 million$3.60 millionViewN/AView Earnings Details
2/19/2013Q4 2012($0.16)($0.22)$4.02 million$4.10 millionViewN/AView Earnings Details
11/8/2012Q312($0.22)($0.19)$4.63 million$5.80 millionViewN/AView Earnings Details
8/2/2012($0.26)($0.25)ViewN/AView Earnings Details
5/7/2012($0.26)($0.13)ViewN/AView Earnings Details
2/16/2012($0.33)($0.29)ViewN/AView Earnings Details
11/2/2011($0.30)($0.32)ViewN/AView Earnings Details
8/4/2011($0.26)($0.36)ViewN/AView Earnings Details
5/4/2011($0.20)($0.29)ViewN/AView Earnings Details
2/10/2011($0.21)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)
2017 EPS Consensus Estimate: ($0.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.14)($0.14)($0.14)
Q2 20171($0.17)($0.17)($0.17)
Q3 20171($0.13)($0.13)($0.13)
Q4 20171($0.12)($0.12)($0.12)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for BioCryst Pharmaceuticals (NASDAQ BCRX)

Insider Ownership Percentage: 5.80%
Institutional Ownership Percentage: 72.06%
Insider Trades by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Insider Trades by Quarter for BioCryst Pharmaceuticals (NASDAQ BCRX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/13/2017William P SheridanCMOSell64,310$4.72$303,543.20View SEC Filing  
9/18/2017Fred E CohenDirectorSell54,250$5.42$294,035.00View SEC Filing  
3/20/2017Thomas R Staab IICFOSell3,250$9.20$29,900.00View SEC Filing  
3/10/2017Thomas R Staab IIInsiderSell3,250$9.06$29,445.00View SEC Filing  
3/8/2017Thomas R Staab IIInsiderSell6,500$8.43$54,795.00View SEC Filing  
3/6/2017Thomas R Staab IIInsiderSell3,250$7.90$25,675.00View SEC Filing  
12/19/2016Thomas R Staab IIInsiderSell3,250$7.45$24,212.50View SEC Filing  
9/14/2016Alane P BarnesVPSell8,357$4.27$35,684.39View SEC Filing  
8/25/2016Yarlagadda S BabuVPSell30,000$4.06$121,800.00View SEC Filing  
8/16/2016Bros. Advisors Lp BakerMajor ShareholderSell4,046,590$5.00$20,232,950.00View SEC Filing  
8/12/2016Thomas R Staab IIInsiderSell5,864$5.18$30,375.52View SEC Filing  
8/9/2016Thomas R Staab IIInsiderSell14,577$4.43$64,576.11View SEC Filing  
1/28/2016Bros. Advisors Lp Bakermajor shareholderBuy88,345$6.95$613,997.75View SEC Filing  
1/22/2016Bros. Advisors Lp Bakermajor shareholderBuy106,800$7.28$777,504.00View SEC Filing  
1/20/2016Bros. Advisors Lp Bakermajor shareholderBuy52,695$6.87$362,014.65View SEC Filing  
1/19/2016Bros. Advisors Lp Bakermajor shareholderBuy92,200$7.12$656,464.00View SEC Filing  
1/15/2016Bros. Advisors Lp Bakermajor shareholderBuy200,000$7.46$1,492,000.00View SEC Filing  
12/21/2015Thomas R Staab IICFOSell3,052$10.86$33,144.72View SEC Filing  
12/17/2015Thomas R Staab IICFOSell3,000$10.49$31,470.00View SEC Filing  
7/20/2015Thomas R Staab IICFOSell3,500$16.50$57,750.00View SEC Filing  
6/22/2015Thomas R Staab IICFOSell3,750$16.00$60,000.00View SEC Filing  
6/19/2015Alane P BarnesVPSell3,000$15.00$45,000.00View SEC Filing  
6/19/2015Jon P StonehouseCEOSell20,000$15.02$300,400.00View SEC Filing  
6/19/2015Thomas R Staab IICFOSell16,375$14.36$235,145.00View SEC Filing  
6/19/2015William P SheridanCMOSell70,389$15.05$1,059,354.45View SEC Filing  
6/5/2015Thomas R Staab IICFOSell6,000$12.75$76,500.00View SEC Filing  
5/18/2015Thomas R Staab IICFOSell3,000$11.00$33,000.00View SEC Filing  
3/19/2015Yarlagadda S BabuVPSell12,105$10.16$122,986.80View SEC Filing  
3/5/2015Yarlagadda S BabuVPSell37,400$10.59$396,066.00View SEC Filing  
3/4/2015Yarlagadda S BabuVPSell10,495$10.50$110,197.50View SEC Filing  
2/20/2015Nancy J HutsonDirectorBuy10,000$10.27$102,700.00View SEC Filing  
12/30/2014William P SheridanCMOSell128,399$12.36$1,587,011.64View SEC Filing  
12/29/2014Thomas R Staab IICFOSell9,500$12.56$119,320.00View SEC Filing  
12/29/2014William P SheridanCMOSell105,295$12.43$1,308,816.85View SEC Filing  
8/27/2014Thomas R Staab IICFOSell10,000$13.58$135,800.00View SEC Filing  
7/1/2014Thomas R Staab IICFOSell3,125$13.00$40,625.00View SEC Filing  
6/23/2014Thomas R Staab IICFOSell3,125$12.49$39,031.25View SEC Filing  
6/17/2014Thomas R Staab IICFOSell3,125$12.00$37,500.00View SEC Filing  
3/14/2014Thomas Staab IICFOSell3,125$11.24$35,125.00View SEC Filing  
3/6/2014Kenneth Lee, Jr.DirectorSell12,665$12.69$160,718.85View SEC Filing  
11/12/2013George AbercrombieDirectorBuy3,000$6.19$18,570.00View SEC Filing  
8/1/2013Felix BakerMajor ShareholderBuy1,136,364$4.40$5,000,001.60View SEC Filing  
3/5/2013George B AbercrombieDirectorBuy3,000$1.23$3,690.00View SEC Filing  
12/14/2012Peder JensenDirectorBuy20,000$1.51$30,200.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for BioCryst Pharmaceuticals (NASDAQ BCRX)

Source:
DateHeadline
$5.77 Million in Sales Expected for BioCryst Pharmaceuticals, Inc. (BCRX) This Quarter$5.77 Million in Sales Expected for BioCryst Pharmaceuticals, Inc. (BCRX) This Quarter
www.americanbankingnews.com - November 18 at 9:58 AM
BioCryst Pharmaceuticals (BCRX) Presents At Jefferies 2017 London Healthcare Conference - SlideshowBioCryst Pharmaceuticals (BCRX) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
seekingalpha.com - November 17 at 4:06 PM
BioCryst Pharmaceuticals, Inc. (BCRX) Receives Average Rating of "Hold" from BrokeragesBioCryst Pharmaceuticals, Inc. (BCRX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 16 at 2:02 PM
William P. Sheridan Sells 64,310 Shares of BioCryst Pharmaceuticals, Inc. (BCRX) StockWilliam P. Sheridan Sells 64,310 Shares of BioCryst Pharmaceuticals, Inc. (BCRX) Stock
www.americanbankingnews.com - November 15 at 8:44 PM
Analysts Issue Forecasts for BioCryst Pharmaceuticals, Inc.s FY2017 Earnings (BCRX)Analysts Issue Forecasts for BioCryst Pharmaceuticals, Inc.'s FY2017 Earnings (BCRX)
www.americanbankingnews.com - November 10 at 8:34 AM
Edited Transcript of BCRX earnings conference call or presentation 7-Nov-17 4:00pm GMTEdited Transcript of BCRX earnings conference call or presentation 7-Nov-17 4:00pm GMT
finance.yahoo.com - November 8 at 12:01 AM
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse Q3 2017 Results - Earnings Call TranscriptBioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 7 at 6:59 PM
BioCryst Reports Third Quarter 2017 Financial ResultsBioCryst Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 6:59 PM
BioCryst reports 3Q lossBioCryst reports 3Q loss
finance.yahoo.com - November 7 at 6:59 PM
Does BioCryst Pharmaceuticals Inc’s (BCRX) Debt Level Pose A Serious Problem?Does BioCryst Pharmaceuticals Inc’s (BCRX) Debt Level Pose A Serious Problem?
finance.yahoo.com - November 7 at 6:59 PM
BioCryst Pharmaceuticals, Inc. (BCRX) Releases Quarterly  Earnings Results, Hits EstimatesBioCryst Pharmaceuticals, Inc. (BCRX) Releases Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - November 7 at 11:15 AM
BioCryst Pharmaceuticals, Inc. (BCRX) Releases Quarterly  Earnings Results, Hits EstimatesBioCryst Pharmaceuticals, Inc. (BCRX) Releases Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - November 7 at 11:15 AM
Horizon Shares Rise on Q3 Results, Guidance -- Biotech MoversHorizon Shares Rise on Q3 Results, Guidance -- Biotech Movers
finance.yahoo.com - November 6 at 5:28 PM
ETFs with exposure to BioCryst Pharmaceuticals, Inc. : November 2, 2017ETFs with exposure to BioCryst Pharmaceuticals, Inc. : November 2, 2017
finance.yahoo.com - November 2 at 5:01 PM
BioCryst to Present at the Jefferies 2017 London Healthcare Conference - GlobeNewswire (press release)BioCryst to Present at the Jefferies 2017 London Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - November 1 at 10:05 PM
BioCryst to Present at the Jefferies 2017 London Healthcare ConferenceBioCryst to Present at the Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 1 at 5:02 PM
BioCryst Pharmaceuticals, Inc. (BCRX) Set to Announce Quarterly Earnings on MondayBioCryst Pharmaceuticals, Inc. (BCRX) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 8:50 AM
BioCryst Pharma (BCRX) Presents Data on Phase 2 APeX-1 Clinical Trial ResultsBioCryst Pharma (BCRX) Presents Data on Phase 2 APeX-1 Clinical Trial Results
www.streetinsider.com - October 28 at 4:50 AM
BioCryst Pharmaceuticals, Inc. (BCRX) Expected to Announce Quarterly Sales of $5.16 MillionBioCryst Pharmaceuticals, Inc. (BCRX) Expected to Announce Quarterly Sales of $5.16 Million
www.americanbankingnews.com - October 28 at 4:16 AM
BioCryst Pharma (BCRX) Presents Data on Phase 2 APeX-1 Clinical Trial Results - StreetInsider.comBioCryst Pharma (BCRX) Presents Data on Phase 2 APeX-1 Clinical Trial Results - StreetInsider.com
www.streetinsider.com - October 27 at 6:45 PM
BioCryst Announces Late Breaker Presentation of BCX7353 Phase 2 APeX-1 Trial Results at the ACAAI’s 2017 Annual Scientific MeetingBioCryst Announces Late Breaker Presentation of BCX7353 Phase 2 APeX-1 Trial Results at the ACAAI’s 2017 Annual Scientific Meeting
finance.yahoo.com - October 27 at 6:45 PM
BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BCRX-US : October 23, 2017BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BCRX-US : October 23, 2017
finance.yahoo.com - October 23 at 5:22 PM
BioCryst Pharmaceuticals, Inc. (BCRX) Receives Consensus Recommendation of "Hold" from AnalystsBioCryst Pharmaceuticals, Inc. (BCRX) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 22 at 2:26 PM
ETFs with exposure to BioCryst Pharmaceuticals, Inc. : October 17, 2017ETFs with exposure to BioCryst Pharmaceuticals, Inc. : October 17, 2017
finance.yahoo.com - October 17 at 5:16 PM
Short Interest in BioCryst Pharmaceuticals, Inc. (BCRX) Drops By 25.1%Short Interest in BioCryst Pharmaceuticals, Inc. (BCRX) Drops By 25.1%
www.americanbankingnews.com - October 13 at 1:32 AM
BioCryst Pharmaceuticals, Inc. (BCRX) Expected to Post Quarterly Sales of $5.16 MillionBioCryst Pharmaceuticals, Inc. (BCRX) Expected to Post Quarterly Sales of $5.16 Million
www.americanbankingnews.com - October 9 at 5:24 AM
Zacks: Analysts Expect BioCryst Pharmaceuticals, Inc. (BCRX) to Announce -$0.17 EPSZacks: Analysts Expect BioCryst Pharmaceuticals, Inc. (BCRX) to Announce -$0.17 EPS
www.americanbankingnews.com - October 7 at 4:08 PM
ETFs with exposure to BioCryst Pharmaceuticals, Inc. : October 3, 2017ETFs with exposure to BioCryst Pharmaceuticals, Inc. : October 3, 2017
finance.yahoo.com - October 3 at 4:13 PM
BioCryst Pharmaceuticals (BCRX) Presents At Cantor Fitzgerald Global Healthcare Conference - SlideshowBioCryst Pharmaceuticals (BCRX) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 28 at 4:47 PM
BioCryst Pharmaceuticals, Inc. (BCRX) Short Interest Up 14.2% in SeptemberBioCryst Pharmaceuticals, Inc. (BCRX) Short Interest Up 14.2% in September
www.americanbankingnews.com - September 28 at 3:18 AM
Few Biotech Stocks Keep Momentum Going With Key Developments and FDA ApprovalsFew Biotech Stocks Keep Momentum Going With Key Developments and FDA Approvals
www.prnewswire.com - September 27 at 7:40 PM
BioCryst Pharmaceuticals (BCRX) Presents At Ladenburg Thalmann 2017 Healthcare Conference - SlideshowBioCryst Pharmaceuticals (BCRX) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Slideshow
seekingalpha.com - September 27 at 7:40 PM
BioCryst Pharmaceuticals, Inc. (BCRX) Receives Consensus Rating of "Hold" from AnalystsBioCryst Pharmaceuticals, Inc. (BCRX) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - September 27 at 2:32 PM
Can BioCryst Turn Itself Around With This FDA Approval? - 24/7 Wall St.Can BioCryst Turn Itself Around With This FDA Approval? - 24/7 Wall St.
247wallst.com - September 23 at 1:27 AM
BioCryst’s RAPIVAB® (peramivir injection) Receives FDA Approval for a Pediatric IndicationBioCryst’s RAPIVAB® (peramivir injection) Receives FDA Approval for a Pediatric Indication
finance.yahoo.com - September 22 at 12:48 PM
Have Investors Already Priced In BioCryst Pharmaceuticals Inc’s (BCRX) Growth?Have Investors Already Priced In BioCryst Pharmaceuticals Inc’s (BCRX) Growth?
finance.yahoo.com - September 22 at 12:48 PM
Can BioCryst Turn Itself Around With This FDA Approval?Can BioCryst Turn Itself Around With This FDA Approval?
finance.yahoo.com - September 22 at 12:48 PM
BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017
finance.yahoo.com - September 22 at 12:48 PM
BioCryst scores FDA approval on flu treatment for childrenBioCryst scores FDA approval on flu treatment for children
finance.yahoo.com - September 22 at 12:48 PM
ETFs with exposure to BioCryst Pharmaceuticals, Inc. : September 22, 2017ETFs with exposure to BioCryst Pharmaceuticals, Inc. : September 22, 2017
finance.yahoo.com - September 22 at 12:48 PM
BioCryst Pharmaceuticals, Inc. (BCRX) Director Fred E. Cohen Sells 54,250 SharesBioCryst Pharmaceuticals, Inc. (BCRX) Director Fred E. Cohen Sells 54,250 Shares
www.americanbankingnews.com - September 20 at 1:16 PM
$5.16 Million in Sales Expected for BioCryst Pharmaceuticals, Inc. (BCRX) This Quarter$5.16 Million in Sales Expected for BioCryst Pharmaceuticals, Inc. (BCRX) This Quarter
www.americanbankingnews.com - September 20 at 3:56 AM
 Brokerages Expect BioCryst Pharmaceuticals, Inc. (BCRX) to Post -$0.17 Earnings Per Share Brokerages Expect BioCryst Pharmaceuticals, Inc. (BCRX) to Post -$0.17 Earnings Per Share
www.americanbankingnews.com - September 18 at 10:28 PM
BioCryst Meeting with FDA to Design Phase III Trial for BCX7353 and PDUFA Review for RAPIVABBioCryst Meeting with FDA to Design Phase III Trial for BCX7353 and PDUFA Review for RAPIVAB
finance.yahoo.com - September 15 at 4:52 PM
BioCryst Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common StockBioCryst Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock
finance.yahoo.com - September 15 at 4:52 PM
BioCryst Pharmaceuticals, Inc. (BCRX) Receives New Coverage from Analysts at Royal Bank Of CanadaBioCryst Pharmaceuticals, Inc. (BCRX) Receives New Coverage from Analysts at Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 11:06 PM
​How BioCryst aims to use its $80M public offering​How BioCryst aims to use its $80M public offering
finance.yahoo.com - September 14 at 5:07 PM
BioCryst Pharma (BCRX) Prices 15.53M Share Common Offering at ... - StreetInsider.comBioCryst Pharma (BCRX) Prices 15.53M Share Common Offering at ... - StreetInsider.com
www.streetinsider.com - September 13 at 10:40 PM
BioCryst Prices Offering At $5.15/ShareBioCryst Prices Offering At $5.15/Share
www.rttnews.com - September 13 at 5:36 PM
BioCryst Pharma (BCRX) Prices 15.53M Share Common Offering at $5.15/ShBioCryst Pharma (BCRX) Prices 15.53M Share Common Offering at $5.15/Sh
www.streetinsider.com - September 13 at 5:36 PM

Social Media

Financials

Chart

BioCryst Pharmaceuticals (NASDAQ BCRX) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.